Asunto(s)
Contractura/radioterapia , Enfermedad Injerto contra Huésped/radioterapia , Articulaciones/fisiopatología , Terapia por Luz de Baja Intensidad/métodos , Piel/patología , Biopsia , Enfermedad Crónica/terapia , Contractura/etiología , Contractura/fisiopatología , Fraccionamiento de la Dosis de Radiación , Enfermedad Injerto contra Huésped/complicaciones , Humanos , Láseres de Gas/efectos adversos , Láseres de Gas/uso terapéutico , Terapia por Luz de Baja Intensidad/efectos adversos , Terapia por Luz de Baja Intensidad/instrumentación , Proyectos Piloto , Estudios Prospectivos , Rango del Movimiento Articular , Esclerosis , Piel/efectos de la radiación , Resultado del TratamientoRESUMEN
PURPOSE OF REVIEW: Diagnosis and management of mycosis fungoides and Sézary syndrome (MF/SS) require accurate clinicopathological correlation and a multidisciplinary approach. We reviewed major advances in the field regarding diagnostic and prognostic tools as well as skin-directed therapies (SDTs) and systemic agents for MF/SS published in the past 2 years. RECENT FINDINGS: Improved technology (T-cell receptor high-throughput sequencing) and increased multicenter collaboration (Cutaneous Lymphoma International Consortium) have led to diagnostic/prognostic advances. Concurrently, numerous genomic studies have enhanced understanding of disease pathogenesis. Advances in SDTs include topical resiquimod, a novel potent Toll-like receptor (TLR) agonist; consensus CTCL phototherapy guidelines; and use of low-dose radiation therapy. Novel systemic therapies for advanced disease of note include targeted antibody drug conjugates (brentuximab vedotin), immune checkpoint inhibitors, and allogeneic hematopoietic stem cell transplantation (HSCT). Our "toolbox" to diagnose and treat the spectrum of MF/SS continues to expand. Further characterization of genomic data going forward will enable a rational approach to selecting and combining therapies to improve patient care.